Home > Publications database > Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0. > print

001     275254
005     20240229162327.0
024 7 _ |a 10.2967/jnumed.122.264489
|2 doi
024 7 _ |a pmid:36302658
|2 pmid
024 7 _ |a 0097-9058
|2 ISSN
024 7 _ |a 0022-3123
|2 ISSN
024 7 _ |a 0161-5505
|2 ISSN
024 7 _ |a 1535-5667
|2 ISSN
024 7 _ |a 2159-662X
|2 ISSN
024 7 _ |a altmetric:137776359
|2 altmetric
037 _ _ |a DKFZ-2023-00701
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kind, Felix
|b 0
245 _ _ |a Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.
260 _ _ |a New York, NY
|c 2023
|b Soc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680770996_21948
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Quantitative evaluation of prostate-specific membrane antigen (PSMA)-targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50% threshold of lesion SUVmax (PSMATV50). In the present study, we analyzed the suitability of this approach comparing 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT scans and the potential of PSMATV50 for the prediction of overall survival (OS) in patients before 177Lu-PSMA radioligand therapy (RLT). Moreover, PSMATV50 was integrated into the PSMA PET/CT consensus statement as well as RECIP 1.0, and the prognostic value of these response classification systems was compared. Methods: This retrospective study included 70 patients with metastatic castration-resistant prostate cancer undergoing PSMA RLT. Thirty-three patients were monitored by 68Ga-PSMA-11 PET/CT, and 37 patients by 18F-PSMA-1007 PET/CT. PET/CT scans before (baseline) and at the end of PSMA RLT after 2-4 cycles (follow-up) were separately analyzed by 2 readers. PSMATV50 at baseline and its change at the time of follow-up (ΔPSMATV50, expressed as a ratio) were correlated with OS using Cox proportional-hazards regression. The results of both subgroups were compared. The integration of ΔPSMATV50 in existing response classification systems was evaluated. To assess and compare the discriminatory strength of these classification systems, Gönen and Heller concordance probability estimates were calculated. Results: PSMATV50 determination was technically feasible in all examinations. A higher PSMATV50 at baseline and a higher ΔPSMATV50 were strongly associated with a shorter OS for both 68Ga-PSMA-11 (PSMATV50: hazard ratio [HR] of 1.29 [95% CI, 1.05-1.55], P = 0.009; ΔPSMATV50: HR of 1.83 [95% CI, 1.08-3.09], P = 0.024) and 18F-PSMA-1007 (PSMATV50: HR of 1.84 [95% CI, 1.13-2.99], P = 0.014; ΔPSMATV50: HR of 1.23 [95% CI, 1.04-1.51], P = 0.03). Response assessment provided high discriminatory power for OS for the PSMA PET/CT consensus statement (concordance probability estimate, 0.73) as well as RECIP 1.0 (concordance probability estimate, 0.74). Conclusion: PSMATV50 and ΔPSMATV50 proved to be predictive of OS not only for 68Ga-PSMA-11 but also for 18F-PSMA-1007 PET/CT scans. Subsequent integration of ΔPSMATV50 into the PSMA PET/CT consensus statement and RECIP 1.0 provided equally high prognostic value for both classification systems.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PSMA PET/CT
|2 Other
650 _ 7 |a PSMATV50
|2 Other
650 _ 7 |a RECIP 1.0
|2 Other
650 _ 7 |a radioligand therapy
|2 Other
650 _ 7 |a response assessment
|2 Other
650 _ 7 |a gallium 68 PSMA-11
|2 NLM Chemicals
650 _ 7 |a Prostate-Specific Antigen
|0 EC 3.4.21.77
|2 NLM Chemicals
650 _ 7 |a Dipeptides
|2 NLM Chemicals
650 _ 7 |a Heterocyclic Compounds, 1-Ring
|2 NLM Chemicals
650 _ 7 |a Lutetium
|0 5H0DOZ21UJ
|2 NLM Chemicals
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Positron Emission Tomography Computed Tomography: methods
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Prostate-Specific Antigen
|2 MeSH
650 _ 2 |a Tumor Burden
|2 MeSH
650 _ 2 |a Prostatic Neoplasms, Castration-Resistant: diagnostic imaging
|2 MeSH
650 _ 2 |a Prostatic Neoplasms, Castration-Resistant: radiotherapy
|2 MeSH
650 _ 2 |a Dipeptides: adverse effects
|2 MeSH
650 _ 2 |a Heterocyclic Compounds, 1-Ring: adverse effects
|2 MeSH
650 _ 2 |a Lutetium
|2 MeSH
700 1 _ |a Eder, Ann-Christin
|0 P:(DE-He78)584449af653618bdd9539e668604ad74
|b 1
|u dkfz
700 1 _ |a Jilg, Cordula A
|b 2
700 1 _ |a Hartrampf, Philipp E
|b 3
700 1 _ |a Meyer, Philipp T
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Ruf, Juri
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Michalski, Kerstin
|b 6
773 _ _ |a 10.2967/jnumed.122.264489
|g Vol. 64, no. 4, p. 605 - 610
|0 PERI:(DE-600)2040222-3
|n 4
|p 605 - 610
|t Journal of nuclear medicine
|v 64
|y 2023
|x 0097-9058
909 C O |o oai:inrepo02.dkfz.de:275254
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)584449af653618bdd9539e668604ad74
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NUCL MED : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NUCL MED : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK FR zentral
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21